Press Releases May 6, 2026 07:30 AM

Crescent Biopharma to Present at May Investor Conferences

Crescent Biopharma Announces Participation in Multiple May 2026 Investor Conferences

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
CBIO

Crescent Biopharma, a clinical-stage biotechnology company specializing in oncology therapies, will present at several investor conferences throughout May 2026, including BofA Securities Healthcare Conference, Stifel Virtual Targeted Oncology Forum, and TD Cowen Oncology Innovation Summit. The events feature virtual and in-person fireside chats focusing on their pipeline progress and company vision.

Crescent Biopharma to Present at May Investor Conferences
CBIO
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Crescent Biopharma is highlighting its PD-1 x VEGF bispecific antibody and novel antibody-drug conjugates (ADCs) in the oncology space.
  • The company is leveraging multiple therapeutic modalities to target a range of solid tumors, aiming at rapid development of transformative cancer treatments.
  • Presentations will occur both virtually and in-person, increasing investor access and visibility.
  • The oncology and biotechnology sectors are primarily impacted, with potential downstream effects on pharmaceuticals and healthcare investment markets.

WALTHAM, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in May:

  • BofA Securities 2026 Healthcare Conference, fireside chat on Wednesday, May 13, 2026 at 4:20 p.m. PT (7:20 p.m. ET) in Las Vegas
  • 2026 Stifel Virtual Targeted Oncology Forum, virtual fireside chat on Wednesday, May 20, 2026 at 2:30 p.m. ET
  • TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA, virtual fireside chat on Tuesday, May 26, 2026 at 11:30 a.m. ET

A live webcast of each presentation will be available in the Investors section of Crescent's website at https://investors.crescentbiopharma.com/events-presentations, and a replay will be accessible for 90 days.

About Crescent Biopharma

Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies either as single agents or as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X.

Contacts

Investors
Amy Reilly
Chief Communications Officer
[email protected]
617-465-0586

Media
Jenna Poist
Director, Corporate Communications
[email protected]
781-671-5019


Risks

  • Clinical-stage development inherently carries risks including trial failures or regulatory delays, which could impact progress and valuation.
  • Market reaction depends on substantive data updates; without new data, investor enthusiasm may be limited.
  • Competitive pressures in the oncology biotech sector from other emerging therapies could affect Crescent’s market positioning and growth.

More from Press Releases

Space Exploration Technologies Corporation to Join the Nasdaq-100 Index® Beginning July 7, 2026 Jun 26, 2026 XMax Announces Up to Approximately US$25 million in AI API-Related Service Contracts and Expansion into GPU-as-a-Service Jun 26, 2026 Cartesian Growth Corporation IV Announces Closing of $275 Million Initial Public Offering Jun 26, 2026 dLocal added to membership of US small-cap Russell 2000® Index Jun 26, 2026 Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance Jun 26, 2026